drugset / Trial / NCT01814839
A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC (revusiran) in healthy volunteer subjects.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-04
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ALN-TTRSC | Unknown | — | Subcutaneous |
Indications
No indication recorded.